Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Return on Equity (2020 - 2025)

Tarsus Pharmaceuticals has reported Return on Equity over the past 6 years, most recently at 0.19% for Q4 2025.

  • Quarterly results put Return on Equity at 0.19% for Q4 2025, up 30.0% from a year ago — trailing twelve months through Dec 2025 was 0.19% (up 30.0% YoY), and the annual figure for FY2025 was 0.23%, up 31.0%.
  • Return on Equity for Q4 2025 was 0.19% at Tarsus Pharmaceuticals, up from 0.24% in the prior quarter.
  • Over the last five years, Return on Equity for TARS hit a ceiling of 0.02% in Q2 2021 and a floor of 0.66% in Q4 2023.
  • Median Return on Equity over the past 5 years was 0.3% (2022), compared with a mean of 0.34%.
  • Biggest five-year swings in Return on Equity: plummeted -35bps in 2023 and later grew 30bps in 2025.
  • Tarsus Pharmaceuticals' Return on Equity stood at 0.07% in 2021, then tumbled by -341bps to 0.31% in 2022, then tumbled by -114bps to 0.66% in 2023, then grew by 26bps to 0.49% in 2024, then skyrocketed by 61bps to 0.19% in 2025.
  • The last three reported values for Return on Equity were 0.19% (Q4 2025), 0.24% (Q3 2025), and 0.27% (Q2 2025) per Business Quant data.